Condensed Consolidated Statement of Cash Flows - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (8,594)	$ (28,057)	$ (72,600)
Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized foreign currency translation adjustment	44	(972)
Amortization of operating lease right-of-use assets	427	369
Share-based compensation expense	1,590	2,135
Depreciation and non-cash amortization	492	426
Non-cash gain on long-term investment	(2,184)	0
Change in operating lease liabilities	(432)	(369)
Other	3	25
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,027)	203
Income tax receivable	(10)	(190)
Other non-current assets	0	340
Accounts payable	(1,442)	1,198
Accrued expenses	(2,370)	7,161
Net cash used in operating activities	(13,503)	(17,731)
Cash flows from investing activities:
Purchases of property and equipment	(19)	(78)
Net cash used in investing activities	(19)	(78)
Cash flows from financing activities:
Payments on long-term debt	(15,731)	(5,047)
Capital contribution received from Roivant Sciences, Inc.	53	28
Cash proceeds from stock option exercises	0	5
Cash proceeds from issuance of common shares, net of issuance costs	3,930	0
Net cash used in financing activities	(11,748)	(5,014)
Net change in cash and cash equivalents	(25,270)	(22,823)
Cash and cash equivalents—beginning of period	80,752	106,999	106,999
Cash and cash equivalents—end of period	55,482	84,176	$ 80,752
Non-cash operating activities:
Operating lease right-of-use assets recognized upon and since the adoption of ASC 842, Leases, on April 1, 2019	0	2,986
Operating lease liabilities recognized upon and since the adoption of ASC 842, Leases, on April 1, 2019	0	2,400
Amounts reclassified from other non-current assets to operating lease right-of-use assets upon the adoption of ASC 842, Leases, on April 1, 2019	$ 0	$ 586